| 영문 | adverse effect | 한글 | 역효과, 유해효과 |
|---|---|---|---|
| 설명 | 약물에 의한 치료를 할 때 나타나는 치료목적에 부합되지 않는 불쾌한 작용, 즉 부작용을 역효과로 표현하는 경우가 있다. 세계보건기구(WHO)에서는 역효과란 “예방, 진단, 치료의 목적으로 사람에게 상용량의 약을 사용하였을 때 발현하는 장애로, 의도하지 않은 작용”이라고 정의하고 있다. 약물에 의한 치료를 할 때, 특히 주목하여야 할 일반적인 역효과로서 약물알레르기, 조혈장기 장애, 간-콩팥의 장애, 물질 대사 장애 등이 있다. 이 외에 임산부에게 투여하여 발생한 기형발생, 마약, 각성제, 기타 향정신제에 의한 의존성 형성도 중요하다. |
||
| HIV | Human Immunodeficiency Virus |
|---|---|
| CD4 | HIV helper cell count |
| CD8 | HIV suppressor cell count |
| HIV | human immunodeficiency virus |
| HIV | Ag human immunodeficiency virus antigen |
| HIV AN | HIV associated nephropathy |
|---|---|
| HIV- | HIV negative |
| HIV+ | HIV positive |
| HIV Pr | HIV protease |
| HIV- | HIV sero-negative |
| anti-HIV agents | Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids. (12 Dec 1998) |
|---|---|
| receptors, HIV | Cellular receptors that bind the human immunodeficiency virus that causes aids. Included are CD4 antigens, found on t4 lymphocytes, and monocytes/macrophages, which bind to the HIV envelope protein gp120. (12 Dec 1998) |
| chronic symptomatic HIV infection | This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening. Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc). (27 Sep 1997) |
| middle stage HIV disease | <disease> This refers to an HIV infection that is characterised by signs and symptoms of HIV that are not life-threatening. Examples include oral thrush, gingivitis, seborrheic dermatitis, molluscum contangiosum, fevers, fatigue, lymph node swelling, malaise and weight loss. This stage can be a signal for the conversion from asymptomatic HIV disease to HIV disease (moe pronouced symptoms include joint pains). AIDS is diagnosed after HIV disease has started to manifest life-threatening oppotunistic infections (for example pneumocystis, cryptosporidium, toxoplasmosis, etc). (27 Sep 1997) |
| primary HIV infection | <infectious disease> The flu-like syndrome that oc immediately after a person contracts HIV. This mini infection precedes seroconversion and is characterised fever, sore throat, headache, skin rash and swollen glands. (06 Mar 1998) |
| HIV | <virology> A type of retrovirus (human immunodeficiency virus) that is responsible for the fatal illness acquired immunodeficiency syndrome. Two strains have been identified. Type 1: the retrovirus recognised as the agent that induces AIDS. Type 2: a virus closely related to HIV-1 that also leads to immune suppression. HIV-2 is not as virulent as HIV-1 and is epidemic only in West Africa. Acronym: HIV (11 Nov 1997) |
| HIV-1 | The type species of lentivirus and widely recognised as the aetiologic agent of acquired immunodeficiency syndrome (aids). It is characterised by its cytopathic effect and affinity for the t4-lymphocyte. (12 Dec 1998) |
| HIV-1 reverse transcriptase | <enzyme> HIV-1 enzyme responsible for the synthesis of DNA from genomic RNA of the virus. It is encoded by the pol gene of HIV-1. Registry number: EC 2.7.7.- (12 Dec 1998) |
| HIV-2 | An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian lentivirus siv and infects only t4-lymphocytes expressing the CD4 phenotypic marker. (12 Dec 1998) |
| HIV-2 protease | <enzyme> Processes hiv-1pr53(gag) and analogous junction peptides in vitro; less than 60% amino acid identity to hiv-1 protease Registry number: EC 3.4.23.- Synonym: hiv2 protease (26 Jun 1999) |
| HIV-2 reverse transcriptase | <enzyme> Responsible for synthesis of double-stranded DNA from the genomic RNA of the virus; has rnase h and DNA-dependent DNA polymerase activities; was indexed as reverse transcriptase (87-91) Registry number: EC 2.7.7.- (26 Jun 1999) |
| HIV antibodies | Antibodies reactive with human immunodeficiency virus (HIV, previously called HTLV-III/lav) antigens of aids. This includes HIV-1 antibodies and HIV-2 antibodies. (12 Dec 1998) |
| HIV antigens | Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (lav) antigens. (12 Dec 1998) |
| HIV core protein p24 | A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by elisa and western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. (12 Dec 1998) |
| HIV encephalopathy | <immunology> A frequent cerebral condition in people with AIDS that results in the loss of cognitive capacity, affecting the ability to function in a social or occupational setting. Its cause has not been determined exactly, but may result from HIV infection of cells in the brain or an inflammatory reaction to such infection. (09 Oct 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|